This Week in Cardiology

Nov 21 2025 This Week in Cardiology

35 snips
Nov 21, 2025
This week, the discussion dives into groundbreaking findings from the CREST-2 trial, revealing new insights into treating carotid artery disease. The ongoing battle between prasugrel and ticagrelor continues, with recent evidence suggesting prasugrel holds an edge for high-risk diabetic patients. Plus, there's an intriguing look at coffee consumption's relationship with atrial fibrillation—could that morning cup actually lower your risk? Tune in for a blend of clinical updates and listener feedback that keeps healthcare professionals engaged!
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Drug Class Versus Individual Agent Effects Are Unclear

  • Class effects versus individual drug effects remain uncertain; trial context and patient selection may explain differing outcomes.
  • Mandrola cites bucindolol and BEST to illustrate how patient fragility and trial populations can drive apparent drug failures.
ADVICE

Focus On Absolute Benefit And Targeting

  • When interpreting lipid-lowering or novel therapy trials, consider absolute benefit and time-to-event delays, not just relative risk.
  • Target therapies to patients with high atherosclerotic burden rather than broadly applying them.
INSIGHT

CREST-2 Shifts Asymptomatic Carotid Care

  • CREST-2 shows minimal absolute benefit from revascularization for asymptomatic carotid stenosis when best medical therapy is used.
  • Mandrola views the data as closing the chapter on routine carotid endarterectomy and argues to prioritize aggressive medical therapy first.
Get the Snipd Podcast app to discover more snips from this episode
Get the app